By Ethan Covey
The use of cell-based quadrivalent seasonal influenza vaccine (QIVc Flucelvax, CSL Seqirus) in children provides both clinical and economic benefits when compared with egg-based QIV (QIVe) vaccines, according to a new study (Vaccines 2023;11[10]:1594).
The study evaluated data from 16 studies over four flu seasons in the United States, the European Union and Southeast Asia.